Effective flow-through polishing strategies for knob-into-hole bispecific antibodies

Abstract

Bispecific antibodies (bsAbs), though possessing great therapeutic potential, are extremely challenging to obtain at high purity within a limited number of scalable downstream processing steps. Complementary to Protein A chromatography, polishing strategies play a critical role at removing the remaining high molecular weight (HMW) and low molecular weight (LMW) species, as well as host cell proteins (HCP) in order to achieve a final product of high purity. Here, we demonstrate using two knob-into-hole (KiH) bsAb constructs that two flow-through polishing steps utilising Capto Butyl ImpRes and Capto adhere resins, performed after an optimal Protein A affinity chromatography step can further reduce the HCP by 17- to 35-fold as well as HMW and LMW species with respect to monomer by ~ 4–6% and ~ 1%, respectively, to meet therapeutical requirement at 30–60 mg/mL-resin (R) load. This complete flow-through polishing strategy, guided by Design of Experiments (DoE), eliminates undesirable aggregation problems associated with the higher aggregation propensity of scFv containing bsAbs that may occur in the bind and elute mode, offering an improved ease of overall process operation without additional elution buffer preparation and consumption, thus aligning well with process intensification efforts. Overall, we demonstrate that through the employment of (1) Protein A chromatography step and (2) flow-through polishing steps, a final product containing < 1% HMW species, < 1% LMW species and < 100 ppm HCP can be obtained with an overall process recovery of 56–87%.

Keywords

Bispecific antibody / Knob-into-hole / Flow-through polishing / Host cell proteins / High molecular weight impurities / Low molecular weight impurities / Higher aggregation propensity

References

[1] Allan B, Glasebrook AL, Leung DDM, Lu J, Tang Y, Vendel AC et al. (2014). Anti-tnf-anti-il-17 bispecific antibodies. WO2014137961 A1, 12 September 2014.

[2] Andrade C, Arnold L, Motabar D, Aspelund M, Tang A, Hunter A, . An integrated approach to aggregate control for therapeutic bispecific antibodies using an improved three column mAb platform-like purification process. Biotechnol Prog, 2019, 35(1

[3] Baehner M, Imhof-Jung S, Kavlie A, Kettenberger H, Klein C, Regula JT et al. (2011). Bispecific, bivalent anti-vegf/anti-ang-2 antibodies. WO2011117329 A1, 29 September 2011.

[4] Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Can Res, 2009, 69(12): 4941-4944.

[5] Bertl S, Duerr H, Schaubmar A. (2015). Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography. WO2015024896 A1, 26 February 2015.

[6] Brinkmann U, Kontermann R. The Making of Bispecific Antibodies. Mabs, 2017, 9(2): 182-212.

[7] Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, . MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol, 2006, 43(8): 1129-1143.

[8] Bruenker P, Daouti S, Feng N, Koller CF, Georges G, Grau-Richards S et al. (2014). Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use. WO2014161845 A1, 9 October 2014.

[9] Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. Mabs, 2009, 1(6): 539-547.

[10] Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antibody Therapeutics, 2021, 4(2): 73-88.

[11] Chen X, Wang Y, Li Y. Removing half antibody byproduct by Protein A chromatography during the purification of a bispecific antibody. Protein Expr Purif, 2020, 172.

[12] Chen SW, Hoi KM, Mahfut FB, Yang Y, Zhang W. Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. Bioresour Bioprocess, 2022, 9: 72.

[13] Cytiva (2020a). Capto S ImpAct Ion Exchange Media 29092501 AD. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=17322 Accessed on 31 Jul 2022.

[14] Cytiva (2020b). Capto Phenyl ImpRes and Capto Butyl ImpRes. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=16471 Accessed on 31 Jul 2022.

[15] Cytiva (2020c). Capto adhere ImpRes. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=16466 Accessed on 31 Jul 2022.

[16] Cytiva (2020d). Capto adhere. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=14882 Accessed on 31 Jul 2022.

[17] Dimasi N, Fleming R, Wu H, Gao C. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies. Methods, 2019, 154: 77-86.

[18] Dorken B, Riethmuller G, Kufer P, Lutterbuse R, Bargou R, Loffler A. (2009). CD19XCD3 specific polypeptides and uses thereof. US7575923 B2, 18 Aug 2009.

[19] Fouque N, Depoisier JF, Wilson K, Vajda J, Müller E, Dabre R. (2016). Methods of purifying bispecific antibodies. WO2016146594 A1, 22 Sep 2016.

[20] Garber K. Bispecific antibodies rise again. Nat Rev Drug Discovery, 2014, 13(11): 799-801.

[21] Geuijen CAW, Kruif CAD, Throsby M, Logtenberg T, Berthold A, Bakker H. (2015). Antibody that binds erbb-2 and erbb-3. WO2015130173 A1, 3 Sep 2015.

[22] Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, . Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [correction (2019) Blood 133(24):2625]. Blood, 2018, 131(14): 1522-1531.

[23] Guo G, Han J, Wang Y, Li Y. A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies. Protein Expr Purif, 2020, 173.

[24] Hall T, Wilson JJ, Brownlee TJ, Swartling JR, Langan SE, Lambooy PK. Alkaline cation-exchange chromatography for the reduction of aggregate and a mis-formed disulfide variant in a bispecific antibody purification process. J Chromatogra b: Analyt Technol Biomed Life Sci, 2015, 975: 1-8.

[25] Hall T, Kelly GM, Emery WR. Use of mobile phase additives for the elution of bispecific and monoclonal antibodies from phenyl based hydrophobic interaction chromatography resins. J Chromatogra b: Analyt Technol Biomed Life Sci, 2018, 1096: 20-30.

[26] Igawa T, Tsunoda H. (2009). Methods of modifying antibodies for purification of bispecific antibodies. US20090263392 A1, 22 Oct 2009.

[27] Jakobsen BK, Harwood N, Liddy NR (2011) T cell receptors. WO2011001152 A1, 6 Jan 2011.

[28] Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, . Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med, 2017, 376(9): 836-847.

[29] Kimerer LK, Pabst TM, Hunter AK, Carta G. Chromatographic behavior of bivalent bispecific antibodies on cation exchange columns. II. Biomolecular perspectives. J Chromatogr A, 2019, 1601: 133-144.

[30] Kimerer LK, Pabst TM, Hunter AK, Carta G. Chromatographic behavior of bivalent bispecific antibodies on hydrophobic interaction chromatography columns. J Chromatogr A, 2020, 1617.

[31] Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, . Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. Mabs, 2012, 4(6): 653-663.

[32] Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin, 2005, 26(1): 1-9.

[33] Kontermann RE. Dual targeting strategies with bispecific antibodies. Mabs, 2012, 4(2): 182-197.

[34] Kufer P, Lutterbuse R, Kohleisen B, Zeman S, Bauerle P. (2007) Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD-19 antibody constructs for the treatment of B-cell related disorders. US20070123479 A1, 31 May 2007.

[35] Kufer P, Raurn T, Hoffmann P, Kischel R, Lutterbuese R, Rau D et al. (2014). Binding molecules for bcma and cd3. WO2014140248 A1, 18 Sep 2014.

[36] Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov, 2019, 18(8): 585-608.

[37] Li Y, Wang Y, Shen P, Zhou W. Matte A. Chapter 8 – A roadmap for IgG-like bispecific antibody purification. Approaches to the purification, analysis and characterization of antibody-based therapeutics, 2020, Amsterdam: Elsevier, 167-179.

[38] Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas Implications for a single-step purification of bispecific antibodies. J Immunol, 1995, 155(1): 219-225.

[39] Manzke O, Tesch H, Diehl V, Bohlen H. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Methods, 1997, 208(1): 65-73.

[40] Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, . Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. Mabs, 2009, 1(2): 128-141.

[41] Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, . Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem, 2021, 296.

[42] Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, . Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med, 2017, 377(9): 809-818.

[43] Ollier R, Wassmann P, Monney T, Fecourt CR, Gn S, Vinu CA, . Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. Mabs, 2019, 11(8): 1464-1478.

[44] Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, . Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection. Antiviral Res, 2017, 141: 155-164.

[45] Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, . Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE, 2013, 8(2

[46] Sharkey B, Pudi S, Moyer IW, Zhong L, Prinz B, Baruah H, . Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. Mabs, 2017, 9(2): 257-268.

[47] Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F, . Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem, 2017, 292(23): 9745-9759.

[48] Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, . A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep, 2015, 5: 17943.

[49] Spiesberger K, Paulfranz F, Egger A, Reiser J, Vogl C, Rudolf-Scholik J, . Large-scale purification of r28M: a bispecific scFv antibody targeting human melanoma produced in transgenic cattle. PLoS ONE, 2015, 10(10

[50] Syed YY. Amivantamab: first approval. Drugs, 2021, 81(11): 1349-1353.

[51] Taki S, Kamada H, Inoue M, Nagano K, Mukai Y, Higashisaka K, . A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy. PLoS ONE, 2015, 10(12

[52] Tang J, Zhang X, Chen T, Wang Y, Li Y. Removal of half antibody, hole-hole homodimer and aggregates during bispecific antibody purification using MMC ImpRes mixed-mode chromatography. Protein Expr Purif, 2020, 167.

[53] Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, . Nanocell targeting using engineered bispecific antibodies. Mabs, 2015, 7(1): 53-65.

[54] Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. Mabs, 2016, 8(4): 828-838.

[55] Tustian AD, Laurin L, Ihre H, Tran T, Stairs R, Bak H. Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity. Biotechnol Prog, 2018, 34(3): 650-658.

[56] Vallera DA, Miller JS (2017) Therapeutic compounds and methods. WO2017062604 A1, 13 Apr 2017.

[57] Yang X, Zhang Y, Wang F, Wang LJ, Richardson D, Shameem M, . Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography. Anal Biochem, 2015, 484: 173-179.

[58] Zhang T, Wan Y, Wang Y, Li Y. Removing a single-arm species by Fibro PrismA in purifying an asymmetric IgG-like bispecific antibody. Protein Expr Purif, 2021, 182.

[59] Zwolak A, Armstrong AA, Tam SH, Pardinas JR, Goulet DR, Zheng S, . Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding. Mabs, 2017, 9(8): 1306-1316.

[60] Zwolak A, Leettola CN, Tam SH, Goulet DR, Derebe MG, Pardinas JR, . Rapid purification of human bispecific antibodies via selective modulation of Protein A binding. Sci Rep, 2017, 7(1): 15521.

Funding

Cytiva Life Sciences (Sweden)

the Agency for Science, Technology and Research (A*STAR), Singapore.